| 应用 |
A selective inhibitor of JAK1 and JAK2. |
| 产品介绍 |
Baricitinib (LY3009104, INCB028050)是一种选择性的JAK1和JAK2抑制剂，IC50分别为5.9 nM和5.7 nM，比作用于JAK3和Tyk2选择性高70和10倍左右，对c-Met和Chk2没有抑制作用。 |
| 备注 |
Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Phase 3. |
| 生化机理 |
Baricitinib, also known as INCB028050 or LY3009104, is a selective JAK1 and JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). |
| 别名 |
1-(乙基磺酰基)-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]-3-氮杂环丁烷乙腈;INCB 028050;LY 3009104;INCB 028050;LY 3009104;INCB028050;LY3009104;LY-3009104;INCB-028050;2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile |
